A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Cancer shared this article with you from Inoreader A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma Via MedWorm Cancer & Oncology Clinical Trials Condition:   Hepatocellular Carcinoma Interventions:   Drug: IBI318;   Procedure: cTACE;   Drug: placebo Sponsor:   Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.